BiotechTube

MA09-hRPE

Phase 1/2Completed
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stargardt's Macular Dystrophy

Conditions

Stargardt's Macular Dystrophy

Trial Timeline

Dec 13, 2011 → Sep 30, 2015

NCT ID
NCT01469832

About MA09-hRPE

MA09-hRPE is a phase 1/2 stage product being developed by Astellas Pharma for Stargardt's Macular Dystrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT01469832. Target conditions include Stargardt's Macular Dystrophy.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (5)

NCT IDPhaseStatus
NCT02463344Pre-clinicalCompleted
NCT02445612Pre-clinicalCompleted
NCT01469832Phase 1/2Completed
NCT01345006Phase 1/2Completed
NCT01344993Phase 1/2Completed

Competing Products

6 competing products in Stargardt's Macular Dystrophy

See all competitors
ProductCompanyStageHype Score
MA09-hRPEAstellas PharmaPre-clinical
23
MA09-hRPEAstellas PharmaPhase 1/2
41
avacincaptad pegol + ShamAstellas PharmaPhase 2
52
hESC-RPEAstellas PharmaPre-clinical
23
SAR422459SanofiPhase 1/2
40
Long term follow up in all patients who received SAR422459 in previous study TDU13583SanofiPhase 2
51

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85